Ono Pharmaceuticals

Ono Pharma is a global pharmaceutical company established in 1717. Ono has a R&D-oriented focus on drug discovery and development, aiming to identify and develop innovative and breakthrough medications for diseases with high unmet medical need. Ono’s key therapeutic areas expand across a wide range of indications. Ono's portfolio includes cancer and supportive care, diabetes, immunology, and Neurology and CNS diseases. The company has a strong commitment to research collaborations through their discovery research alliance group. Results of that is Ono’s PD1 antibody that arose from a collaboration between the company and a research group from Kyoto University.

In 2022, UK DRI and Ono Pharma launched a funding initiative to support early-stage translational therapeutics in neurodegeneration. The partnership supports postdoctoral research-level projects to undertake novel target identification in a UK DRI research group. This collaboration benefits from the expertise in neurodegenerative diseases held at the UK DRI and in-kind support from the state-of-the-art facilities from the institute, as well as Ono’s internal capabilities in several drug modalities and the company’s expertise in bringing therapeutic programs into the public use. The partnership kicked-off with two projects to study novel pathways and targets in AD and mitochondrial diseases, respectively.